Raymond James Financial enters its July 22 earnings window on the back of a sharp 10.2% weekly gain, trading at $167.60, yet the most striking feature of the setup is not the rally itself — it is how little anxiety surrounds it.
Options positioning is unusually bullish for a stock two weeks from a print. The put/call ratio has dropped to 0.35, well below its 20-day average of 0.42 and near the lower end of its 52-week range of 0.22–1.63. At roughly three-quarters of a standard deviation below the mean, the options market is not hedging this move — it is leaning into it. That contrasts sharply with the mid-June period, when the PCR was running above 0.55 consistently, suggesting the sentiment shift is recent and decisive.
Short interest tells a similarly unconcerned story on the bear side. At 5.3% of free float — modest for a financial services name — short positions have edged down about 1.8% on the week and remain comfortably below the one-month high of roughly 11.1 million shares hit on July 1. Borrow conditions offer no added pressure: cost to borrow is 0.52%, low by any standard, and availability is extraordinarily loose at 1,289% — meaning lenders are holding roughly thirteen times more shares available than are currently borrowed. The ORTEX short score sits at 49.4, near the middle of its range and drifting slightly lower all week. Shorts are present but not pressing.
The Street is cautiously constructive but not enthusiastic. UBS raised its target to $175 from $166 on July 8, maintaining Neutral — a vote of confidence in the rally while stopping short of an upgrade. That action follows a pattern from April, when Morgan Stanley lifted its target modestly to $172 and Barclays moved to $182, both holding existing ratings. The consensus mean target of $177.92 leaves only about 6% upside from current levels, which frames the stock as fairly valued rather than deeply cheap. The bull case centres on RJF's wealth management franchise, its scale across US advisory networks, and the tailwind from capital markets activity. Bears point to EPS estimates running at or below consensus, management softening margin guidance, and questions around client cash growth and loan-to-deposit ratios. On valuation, the trailing P/E of 12.5x has expanded by roughly 0.8x over the past thirty days, tracking the rally, while the price-to-book of 2.26x has risen by 0.16x over the same period. The 12-month forward EPS growth factor scores in the 90th percentile, suggesting the Street sees earnings acceleration ahead even if near-term estimates are tight.
Ownership adds one notable structural feature. Thomas James — the firm's founder — holds 9.8% of shares, a position that slipped by roughly 160,000 shares in the most recent filing. BlackRock added 138,000 shares and Wellington built a fresh 1-million-share position, both pointing to institutional accumulation on the passive and active side. The insider data is stale (last meaningful transaction in March), so no fresh signal there.
The immediate historical earnings record gives some context for what July 22 might bring. The May 2026 print produced a 6.7% one-day drop — the largest reaction in the recent history — while the April 2026 print saw only a 0.7% decline. The stock's tendency to sell off on the day, even modestly, has been consistent. That makes the current optimism in options — a PCR close to its 52-week low — worth watching: the setup is bullish going in, but the pattern of day-one disappointments has been real. With the stock having already run 10% in a week, the July 22 release will test whether the positioning reflects genuine confidence or simply momentum that got ahead of itself.
See the live data behind this article on ORTEX.
Open RJF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
